The new weight loss drug that should work without common side effects
TDP is a smaller version of octadecaneuropeptide (ODN), a protein produced by brain cells called glia, which researchers believe targets energy-regulating pathways in the brain.
Animal studies on mice, rats, and shrews showed that TDP led to weight loss and improved blood sugar control without inducing adverse gastrointestinal reactions.
The findings, published in the journal Science Translational Medicine, are currently a proof of concept based solely on these animal trials.
Researchers, including Caroline Geisler from the University of Kentucky, are hopeful that human clinical trials for TDP could commence within the next two years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
2 hours ago
- BBC News
Wegovy maker Novo Nordisk warns of slower profits as rivals bite
The Danish-maker of Wegovy and Ozempic has warned that its full-year sales and profits will not grow as quickly as expected as more "knock-off" weight-loss drugs Nordisk's share price tumbled by more than 20% as it cut its outlook and named a new chief executive to replace Lars Fruergaard Jørgensen, whose surprise exit was announced in Mike Doustdar, currently vice president of Novo Nordisk's international business, will take over on 7 August. As well as slower-than-forecast growth for Wegovy in the US obesity market, Novo Nordisk also said that sales of Ozempic to Americans with diabetes would be lower. Novo Nordisk has seen its market value tumble as other weight-loss treatments have come onto the its trading update, Novo Nordisk claimed that since May more "unsafe and unlawful" drugs have been released. The company said it "is pursuing multiple strategies, including litigation, to protect patients from knock-off 'semaglutide' drugs".Semaglutide injections are used to treat diabetes but, in recent years, have become wildly popular with people looking to lose weight, especially after the enforced lockdowns of Covid. While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts said the company had been too slow to pursue the market for people willing to pay for its weight-loss treatments. Markus Manns, a portfolio manager at Union Investment, which is a shareholder in Novo Nordisk, said that its "problems are much deeper" than Wegovy in the US and extend to the international market."Novo has underestimated the self-pay market in obesity and just recently started to focus on this important patient segment," he Manns also described the cuts to Novo's growth outlook as "a shocker". Full-year profit is now expected to expand by 10% and 16%, down from an increase of between 16% and 24% predicted in are predicted to increase by between 8% and 14%. In May, Novo forecast growth of between 13% and 21%.Benjamin Jackson, an analyst at Jeffries, questioned why Novo Nordisk has decided to appoint an internal candidate to replace Mr Jø Doustdar first joined Novo Nordisk in 1992. The company said that he had been appointed "as the result of a comprehensive process that included external and internal candidates".But Mr Jackson said: "We are surprised by the appointment of Mike Doustdar as chief executive with feedback suggesting an external candidate may have been preferred."
Telegraph
3 hours ago
- Telegraph
Greggs to target customers on weight-loss drugs
Greggs is to target customers on weight-loss drugs by rolling out smaller portions and protein-rich alternatives as it battles a slowdown in sales. Roisin Currie, the chief executive, said there was 'no doubt' that the injections were changing 'what and how' people eat, and that the bakery chain was looking at adapting its range to suit these customers. It came as shares in Greggs plunged to their lowest level since the pandemic after it said weaker demand for its sausage rolls and other baked goods dealt a £10m blow to profits. Ms Currie said: 'If anyone is on a GLP-1 [weight-loss drug], we know they still need to eat, but what they need to eat starts to change and the portions that they start to eat are changing. 'That's really important for us and making sure that we have got a variety of protein-led options in our range, and also making sure that we've got some of the snack products that customers are looking for if they are on any of the GLP-1 drugs.'
Reuters
3 hours ago
- Reuters
VIEW Reaction to new Novo Nordisk CEO, profit warning
July 29 (Reuters) - Novo Nordisk ( opens new tab on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut its full year outlook for the second time in 2025, sending its shares tumbling. Here are some reactions from market analysts and investors: MARKUS MANNS, A PORTFOLIO MANAGER AT MUTUAL FUNDS FIRM UNION INVESTMENT AND A SHAREHOLDER IN THE COMPANY: "While most people had expected Novo to just trim the top end of the guidance, the magnitude of the guidance cut is a shocker. Novo's problems are much deeper than just compunded Wegovy in the U.S. and extend to the international Wegovy franchise and even to Ozempic in diabetes. Novo has underestimated the self pay market in obesity and just recently started to focus on this important patient segment." JEFFERIES ANALYST BENJAMIN JACKSON ON NEW CEO: "We are surprised by the appointment of Mike Doustdar as CEO, with feedback suggesting an external candidate may have been preferred." ANALYSTS ON THE PROFIT WARNING: "Lowered guidance (is) a reflection of growth expectations in H2'25 for both Wegovy and Ozempic." CITI ANALYSTS ON THE PROFIT WARNING: "We caution against over-reading into Novo's assessment, given tirzepatide's script strength pre-July 1st has been robust and Lilly may have had a more conservative outlook on expectations when giving its own 2025 guidance. Thus, we remain buyers on weakness." ANGELO MEDA, PORTFOLIO MANAGER AND HEAD OF EQUITIES AT BANOR SIM IN MILAN: "The biggest concern is the illegal channel siphoning away market share—something that's hard to quantify. Rebuilding trust will take time."
